GSK to acquire Nuvalent for $10.6B ($124/share), gaining two late-stage lung cancer drugs

Filed June 9, 2026 · Period ending June 9, 2026 · ~2 min read

Key Changes

• high

  GSK agreed to acquire Nuvalent for $124.00 per share in cash via tender offer and merger, representing a 40% premium to the last closing price and valuing the company at $10.6 billion ($9.4B net of cash).

  Item 1.01 — Entry into a Material Definitive Agreement verify on EDGAR →
• high

  The acquisition includes two late-stage lung cancer drugs under FDA review: zidesamtinib (ROS1 inhibitor, decision target Sept 18, 2026) and neladalkib (ALK inhibitor, decision target Nov 27, 2026), both with Breakthrough Therapy designation and multi-blockbuster potential.

  Exhibit 99.1 verify on EDGAR →
• high

  Stockholders holding ~28% of Class A shares—including Deerfield Management, directors, and officers—committed to tender, significantly de-risking the majority tender condition required to close the deal.

  Item 1.01 — Entry into a Material Definitive Agreement verify on EDGAR →